- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00279214
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
August 26, 2009 updated by: Eli Lilly and Company
An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
43
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Ohio
-
Akron, Ohio, United States, 44307
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion:
- 18 years of age or older with a diagnosis of septic shock
- presence of a pulmonary artery catheter (or central venous catheters)
- requiring vasopressor support despite adequate fluid resuscitation
- an intravenous steroid administered for septic shock, except for those patients who were tested and are responders to a corticotropin stimulation test, or patients who do not receive a steroid due to the clinical judgment of the treating physician, based on an alternate assessment (e.g. normal baseline cortisol).
Exclusion:
- Onset of first-sepsis induced organ dysfunction is greater than 24 hours from the time of informed consent
- Baseline measurements of pulmonary artery occlusive pressure (PAOP) < 12 mmHg or a central venous pressure (CVP) < 8 mmHg
- Patient requires continuous oxygen therapy by face-mask
- The presence of an advanced directive to withhold life-sustaining treatment, with the exception of a directive to withhold chest compressions only
- Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Weight > 200 kg
- Are moribund (not expected to survive 24 hours)
- Are pregnant or are lactating and the milk is to be ingested by the infant (pregnancy status must be verified by urine or serum testing)
- Have not completed written informed consent signed by the patient or the patient's legal representative.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Vasopressor Index (CVI)
Time Frame: baseline to 24 hours
|
CVI is sum of rankings for all vasopressors being used by patient at given time.
Based on relative potency and dosing range for each vasopressor, each vasopressor was assigned ranking of 1 (low dosage) to 4 (high dosage).
Range of CVI is between 1 and 20.
|
baseline to 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to 96 Hour Endpoint in Cumulative Vasopressor Index (CVI)
Time Frame: Baseline, 96 hours
|
CVI is sum of rankings for all vasopressors being used by patient at given time.
Based on relative potency and dosing range for each vasopressor, each vasopressor was assigned ranking of 1 (low dosage) to 4 (high dosage).
Range of CVI is between 1 and 20.
|
Baseline, 96 hours
|
Mean Arterial Pressure
Time Frame: baseline to 24 hours
|
baseline to 24 hours
|
|
Cardiovascular Performance Measures Obtained With a Pulmonary Artery Catheter - Cardiac Index
Time Frame: Baseline to 24 Hours
|
Cardiac Index = cardiac output divided by body surface area.
|
Baseline to 24 Hours
|
Lactate Level
Time Frame: Baseline to 6 Hours
|
Measures of global tissue perfusion and oxygenation were assessed via lactate levels.
|
Baseline to 6 Hours
|
Microcirculatory Measures From Sidestream Darkfield (SDF) Microscopy - Small Vessel Microvascular Flow Index (MFI)
Time Frame: Baseline to 24 Hours
|
Per vessel category (and per quadrant), scored flow as follows: no flow=0, intermediate flow=1, sluggish flow=2, continuous flow=3.
The MFI per vessel category calculated with formula (Q1+Q2+Q3+Q4)/4.
Scores could range from 0 (sluggish flow) to 3 (continuous flow).
|
Baseline to 24 Hours
|
Sequential Organ Failure Assessment (SOFA) Score at Baseline and 24 Hours
Time Frame: Baseline and 24 Hours
|
The presence of 5 organ dysfunctions (cardiovascular, respiratory, renal, hepatic, coagulation) was assessed using a Sequential Organ Failure Assessment (SOFA) score.
Each organ has a possible dysfunction score of 0 to 4, for a total SOFA score range of 0 (no organ dysfunction) to 20 (all organs with dysfunction).
|
Baseline and 24 Hours
|
Change From Baseline in Creatinine Clearance (CrCl) at 24 Hours
Time Frame: Baseline and 24 hours
|
CrCl = (urine creatinine*urine volume)/(plasma creatinine*time period of urine collection).
Corrected CrCl = CrCl*1.73/body
surface area.
Change in CrCl = Endpoint minus baseline.
|
Baseline and 24 hours
|
7 Day All-cause In-hospital Mortality
Time Frame: baseline to 7 days
|
baseline to 7 days
|
|
Endogenous Protein C Level
Time Frame: Baseline to 24 Hours
|
Baseline to 24 Hours
|
|
Mixed Venous Oxygen Saturation
Time Frame: Baseline to 24 Hours
|
Cardiovascular performance measures obtained with a pulmonary catheter as assessed by mixed venous oxygen saturation.
|
Baseline to 24 Hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Bleeding Events
Time Frame: baseline to 7 days
|
Serious bleeding event resulted in one of following outcomes, or was significant for any reason: initial/ prolonged inpatient hospitalization; life-threatening experience; persistent or significant disability/incapacity; congenital anomaly/birth defect.
Intracranial hemorrhage was also considered serious bleeding event.
|
baseline to 7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-651-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2005
Study Completion (Actual)
November 1, 2007
Study Registration Dates
First Submitted
December 15, 2005
First Submitted That Met QC Criteria
January 17, 2006
First Posted (Estimate)
January 19, 2006
Study Record Updates
Last Update Posted (Estimate)
September 2, 2009
Last Update Submitted That Met QC Criteria
August 26, 2009
Last Verified
August 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9944 (Other Identifier: CTEP)
- F1K-US-EVDA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on drotrecogin alfa (activated)
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedSepsisUnited States, Canada, Brazil, Mexico, Australia, Czech Republic, Slovakia, Spain, Austria, Belgium, Chile, Denmark, Egypt, Finland, France, Germany, India, Italy, Lebanon, Netherlands, New Zealand, Norway, Romania, Russian Federation, Saudi... and more
-
Eli Lilly and CompanyCompletedSepsis | Hematologic Neoplasms | Infection | Hematopoietic Stem Cell TransplantationUnited States
-
Eli Lilly and CompanyCompletedSepsisUnited States, United Kingdom, France, Slovakia, Switzerland, Australia, Poland, Italy, Chile, Germany, Mexico
-
Eli Lilly and CompanyCompletedSepsisItaly, United Kingdom, United States, Germany, Spain, Belgium, France, Australia, Czech Republic, Netherlands, Canada, Mexico, New Zealand, Finland, Portugal, Brazil, India, Switzerland
-
Eli Lilly and CompanyCompletedSepsis | HypotensionFrance, United States
-
Eli Lilly and CompanyCompletedSevere SepsisUnited States, Belgium, Spain, France, Finland, Germany, Canada, United Kingdom, Puerto Rico
-
George Washington UniversityEli Lilly and CompanyCompletedEnd Stage Renal DiseaseUnited States
-
Eli Lilly and CompanyCompletedSepsisCanada, Finland, Belgium, Argentina, Chile, Australia, Austria, Brazil, Czech Republic, Denmark, Egypt, France
-
Eli Lilly and CompanyCompletedSubmassive Pulmonary EmbolismGermany